Loading patent…
AssigneesAugmenta Bioworks, Inc., TFF Pharmaceuticals, Inc., Board of Regents, The University of Texas System
InventorsChristopher J. EMIG, Steven J. HENRY, Adela Anne VITUG, Dale J. CHRISTENSEN, Zhengrong CUI, Haiyue XU, Robert O. WILLIAMS, III
Estimating the term…
The invention generally encompasses a human-derived monoclonal antibody compositions and methods comprising a dry powder formulation for neutralizing SARS-CoV-2 and known variants thereof in a patient, comprising administering to the patient a dry powder formulation comprising the human-derived monoclonal antibody. The invention further encompasses compositions and methods comprising a dry powder formulation for treating or preventing COVID-19 and/or at least one symptom associated with COVID-19 in a patient, comprising administering to the patient a dry powder formulation comprising the human-derived monoclonal antib.
A dry powder formulation for neutralizing SARS-CoV-2 and known variants thereof in a subject in need thereof comprising administering to the patient the dry powder composition comprising a human-derived monoclonal antibody AUG-3387.
A method for neutralizing SARS-CoV-2 virus in a subject in need thereof, comprising administering to said subject a dry powder formulation comprising human-derived monoclonal antibody, AUG-3387.
21-43. (canceled)
Dependencies are inferred from the claim text.